Physician profile
Mark L Thng
NPI 1225059769
$4,073.47
in general payments reported to CMS, 2019-2025
19 companies · $140 in 2025
The $140 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $955 · 2021: $718 · 2022: $224 · 2023: $199 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $861.03 | 2019-2025 | |
| Abbvie INC. | $574.83 | 2021-2025 | Avycaz, Vraylar |
| Allergan, INC. | $390.30 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $333.56 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $313.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $251.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $235.56 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $233.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.42 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $142.41 | 2019 | |
| Merck Sharp & Dohme LLC | $124.05 | 2019 | |
| Edwards Lifesciences Corporation | $121.75 | 2021 | |
| Vifor Pharma, INC. | $114.21 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.09 | 2020 | |
| Opko Pharmaceuticals, LLC | $43.71 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39.96 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $22.79 | 2019 | |
| Mylan Specialty L.P. | $22.06 | 2019 | |
| Melinta Therapeutics, LLC | $16.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Thng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.